ClinicalTrials.gg
CompletedNCT01995136Updated Oct 7, 2015Results posted

Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma

A Phase 4 interventional study of Travoprost Ophthalmic Solution 0.004% in Normal Tension Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-10-07.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate IOP reduction efficacy of travoprost 0.004% ophthalmic solution (TRAVATAN Z®) in subjects with normal tension glaucoma.

02

Conditions studied

  • Normal Tension Glaucoma
  • Ocular Hypertension

Keywords

  • Glaucoma
  • Ocular hypertension
03

In context

Low Tension Glaucoma

65 studies on the registry are indexed under Low Tension Glaucoma; 9 are open to participants now.

This study's enrollment of 32 is below the median of 42 across 32 interventional studies indexed under Low Tension Glaucoma.

Browse Low Tension Glaucoma studies →

Lead sponsor

Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.

Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of normal tension glaucoma.
  • Must sign an form.
  • IOP within protocol-specified range.
  • Other protocol-specified inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Pregnant and lactating women, or women who intend to become pregnant during the study period.
  • Advanced and serious glaucoma, as specified in protocol.
  • Complicated chronic or recurrent uveitis, scleritis or corneal herpes.
  • History of ocular trauma, intraocular surgery or laser surgery for the included eye.
  • Ocular-infection and severe ocular complication.
  • Best-corrected visual acuity (BCVA) worse than 0.2 decimal.
  • Difficulty in conducting applanation tonometry for the included eye as determined by the doctor.
  • Severe or serious to prostaglandin analogues or any ingredients used in the study.
  • Use of IOP lowering ophthalmic solutions other than TRAVATAN Z® or oral carbonic anhydrase inhibitor (Diamox, etc.) during the study period.
  • Use of any adrenocorticosteroids during the study period.
  • Use of IOP lowering ophthalmic solution within the past 30 days.
  • Regarded by doctor as not suitable for study participation.
  • Other protocol-specified exclusion criteria may apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    TRAVATAN Z

    Travoprost Ophthalmic Solution 0.004%, 1 drop instilled in each eye once daily at 9PM for 3 months.

    Drug: Travoprost Ophthalmic Solution 0.004%

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in IOP (9:00 AM) at Week 4, Week 8, and Week 12

    IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). Data at 9:00 AM from Weeks 4, 8, and 12 were pooled. A more negative change indicates a greater amount of improvement. One eye (study eye) was subject to analysis.

    Time frame: Baseline (Day 0), Week 4, Week 8, Week 12

07

Results

Posted Jul 20, 2015

Participant flow

Subjects were recruited from 5 study sites located in Japan.

Participant flow — Overall Study
MilestoneTRAVATAN Z
Started32
Completed31
Not completed1
Withdrew: Change in residence1

Outcome measures

PrimaryMean Change From Baseline in IOP (9:00 AM) at Week 4, Week 8, and Week 12

IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). Data at 9:00 AM from Weeks 4, 8, and 12 were pooled. A more negative change indicates a greater amount of improvement. One eye (study eye) was subject to analysis.

Time frame:
Baseline (Day 0), Week 4, Week 8, Week 12
Reported as:
Least squares mean · mmHg
Mean Change From Baseline in IOP (9:00 AM) at Week 4, Week 8, and Week 12
mmHgTRAVATAN Z
Baseline16.55 (15.88 to 17.22)
Change from Baseline-3.37 (-3.90 to -2.85)

Adverse events

Collected over Adverse events (AEs) were collected for the duration of the study (Sep 2013 - Jun 2014). This analysis population includes all subjects enrolled in the study, minus any subject whose safety evaluation data is all missed (1 subject).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TRAVATAN Z—0/31 (0%)0/31 (0%)

Baseline characteristics

This analysis population includes all enrolled subjects minus any subjects with all missing data and/or critical protocol deviation/s.

Age, Continuous
Age, Continuous(years)TRAVATAN Z
Mean65.6 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)TRAVATAN Z
Female18
Male12
Baseline IOP
Baseline IOP(mmHg)TRAVATAN Z
9:00 AM16.55 ± 1.43
1:00 PM15.72 ± 1.82
5:00 PM15.73 ± 2.17
08

Study locations

1 site
  • Alcon Japan, Ltd.
    Tokyo, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2013
First posted
Nov 26, 2013
Start
Sep 2013
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Results first posted
Jul 20, 2015
Last update
Oct 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01995136
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Nov 26, 2013
Start date
Sep 2013
Primary completion
Jun 2014
Completion
Jun 2014
Results posted
Jul 20, 2015
Last update
Oct 7, 2015

Study contacts

Danyel Carr, MS
study director · Alcon Japan, Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion